-- 周一午盘,欧洲股市跟随下跌,交易员们正在权衡有关德黑兰将不会参与与华盛顿的和平谈判的报道,此前伊朗和美国均表示霍尔木兹海峡基本对航运关闭。 泛欧斯托克600指数午盘下跌1.1%。 北海布伦特原油近月期货上涨5.4%,至每桶95.29美元。 石油股领涨欧洲大陆市场,而银行股和科技股表现落后。 投资者还关注着华尔街股指期货,该股在隔夜亚洲交易所收盘走高后发出红色信号。 经济方面,德国联邦统计局(Destatis)报告称,德国3月份生产者价格指数同比下降0.2%,但环比上涨2.5%,后者主要受能源价格上涨的影响。 欧洲斯托克600科技指数下跌1.5%,银行指数下跌1.9%。 欧洲斯托克600石油天然气指数上涨1.6%,食品饮料指数下跌1.3%。 欧洲房地产投资信托指数(REITE)下跌1.4%。 各国股市指数方面,德国DAX指数下跌1.4%,伦敦富时100指数下跌0.7%,巴黎CAC 40指数下跌1.2%,西班牙IBEX 35指数下跌1.3%。 德国10年期国债收益率走高,接近3%。 欧洲斯托克50指数波动率上涨15%至22.43,表明未来30天欧洲股市波动性将高于平均水平,这是一个负面信号。该指数高于20预示着市场波动将加剧,而低于20则表明市场交投较为平静。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.